N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: A physiologic biomarker, but is it a clinical tool?

Pediatric Cardiology

Volumn 31, Issue 1, 2010, Pages 62-65

  Hammerman, Cathy ^a,b   Shchors, Irena ^a   Schimmel, Michael S ^a,b   Bromiker, Ruben ^a   Kaplan, Michael ^a,b   Nir, Amiram ^a,b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Patent ductus arteriosus; Pro BNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; IBUPROFEN; INDOMETACIN;

ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; HEMODYNAMICS; HUMAN; MONOTHERAPY; NEWBORN; PATENT DUCTUS ARTERIOSUS; PREMATURITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; DRUG MONITORING; DUCTUS ARTERIOSUS, PATENT; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INFUSIONS, INTRAVENOUS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY;

EID: 75549088380     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-009-9568-1     Document Type: Article

References (8)

1. M Choi KH Lee BL Eun KH Yoo YS Hong CS Son JW Lee 2005 Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants Pediatrics 115 e255 e261 10.1542/peds.2004-1837 15687418 (Pubitemid 43373007)
2. C Czernik J Lemmer B Metze PS Koehne C Mueller M Obladen 2008 B-type natriuretic peptide to predict ductus intervention in infants < 28 weeks Pediatr Res 64 286 290 10.1203/PDR.0b013e3181799594 1:CAS:528: DC%2BD1cXpslalu78%3D 18414139
3. IO Farombi-Oghuvbu T Matthews PD Mayne H Guerin D Corcoran 2008 N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus Arch Dis Child Fetal Neonatal Ed 93 F257 F260 10.1136/adc.2007.120691 1:STN:280:DC%2BD1czpslymsg%3D%3D 18218660 (Pubitemid 352039393)
4. PA Flynn RL DaGraca P Auld M Nesin C Kleinman 2005 The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates J Pediatr 147 38 42 10.1016/j.jpeds.2005.03.040 1:CAS:528:DC%2BD2MXmt1Wgtr8%3D 16027692 (Pubitemid 40981143)
5. C Hammerman I Shchors S Jacobson MS Schimmel R Bromiker M Kaplan A Nir 2008 Ibuprofen vs. continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration? Pediatr Res 64 291 297 10.1203/PDR.0b013e31817d9bb0 1:CAS:528:DC%2BD1cXpslalu7g%3D 18458658
6. H Holmstrom C Hall E Thaulow 2001 Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants Acta Paediatr 90 184 191 10.1080/080352501300049406 1:STN:280:DC%2BD3M7nsVKnug%3D%3D 11236049 (Pubitemid 32222804)
7. VF Puddy C Amirmansour AF Williams DRJ Singer 2002 Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants Clin Sci 103 75 77 10.1042/CS20020046 1:CAS:528:DC%2BD38XmtVSrs74%3D 12095406
8. S Sanjeev M Pettersen J Lua R Thomas S Shankaran T L'Ecuyer 2005 Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates J Perinatol 25 709 713 10.1038/sj.jp.7211383 1:CAS:528:DC%2BD2MXhtFCru77N 16222347 (Pubitemid 41655645)